Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier


    EHA Delphine Rea






    Factors affecting clinical decision making in refractory and relapsed CP-CML patients
    Delphine Réa, Centre Hospitalo-Universitaire Saint-Louis, Paris, France

    • TKI resistance: significance and definition 
    • BCR-ABL1 mutations and resistance to imatinib and 2nd generation TKI's
    • Failure of 1st and 2nd generation TKI's
    • Mortality and causes of death in CP-CML patients during 2nd or subsequent line TKI
    • Responses to 3rd line therapy after resistance or intolerance to 2nd generation TKI
    • 5-year results from the PACE study: Responses to ponatinib in CP-CML patients
    • Therapeutic innovation: allosteric inhibition of BCR-ABL1 by ABL001
    • Conclusion and perspective

    This presentation is adapted from one given during the industry sponsored symposium at EHA.